spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  HRPC 

 HSMN NewsFeed - 26 Mar 2025
Supira Medical Secures $120M Oversubscribed Series E Financing and Completes Enrollment of SUPPORT I Early Feasibility Study in the United States
Devices Interventional Cardiology Venture Capital
 HSMN NewsFeed - 5 Sep 2023
First Patient with NyokAssist(TM) Interventional Ventricular Assist Device: Dr. Junbo Ge's team successfully completed the first high-risk PCI treatment supported by the new generation of interventional VAD
Devices Interventional Cardiology
 HSMN NewsFeed - 16 Sep 2022
Supira Medical Announces Successful First-In-Human Use Of Its Next Generation Percutaneous Ventricular Assist Device
Devices Interventional Cardiology
 HSMN NewsFeed - 8 May 2019
ReNeuron Provides Business Update and Results Notification
Regenerative Medicine Ophthalmology Neurology
 HSMN NewsFeed - 9 Mar 2017
New Study Finds Abiomed Impella(R) Heart Pump Reduces Injury to Kidneys During High-Risk Percutaneous Coronary Intervention
Devices Interventional Cardiology
 HSMN NewsFeed - 23 Aug 2011
FDA Grants Fast Track Designation to Bayer's Investigational Compound Radium-223 Chloride for the Treatment of Castration-Resistant Prostate Cancer That Has Spread to the Bone
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Jun 2011
Bayer's Investigational Compound Radium-223 Chloride Met its Primary Endpoint of Significantly Improving Overall Survival in a Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Oct 2010
Phase III Data Showing Improved Survival With Jevtana(R) (cabazitaxel) Injection in Second-Line Advanced Prostate Cancer Published in The Lancet
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2010
Bayer Presents Clinical Data on Alpharadin in Metastatic Castration-Resistant Prostate Cancer (CRPC)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Mar 2010
Genentech Provides Update on Phase III Study of Avastin in Men With Late Stage Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2008
Algeta Appoints Andrew Kay as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Jun 2008
Data from Satraplatin SPARC Phase 3 Trial in Patients with Hormone-Refractory Prostate Cancer Progressing after Initial Chemotherapy Presented at 44th ASCO Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Oct 2007
GPC Biotech and Pharmion Announce Results of Overall Survival Analysis from the Satraplatin Pivotal Phase 3 Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Oct 2007
Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jul 2007
Marketing Authorization Application for Satraplatin Accepted for Review by the European Medicines Agency
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Jun 2007
Pharmion Submits European Marketing Authorization Application for Satraplatin in Combination With Prednisone for the Treatment of Patients With Metastatic Hormone-Refractory Prostate Cancer Who Have Failed Prior Chemotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Jun 2007
GPC Biotech Announces that Partner Pharmion Submits European Marketing Application for Satraplatin
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 May 2007
Additional Satraplatin Efficacy Data From Phase 3 SPARC Trial Presented at Annual Meeting of American Urological Association
Biopharmaceuticals Oncology Urology
 HSMN NewsFeed - 16 Apr 2007
FDA Accepts Satraplatin NDA And Grants Priority Review
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Apr 2007
FDA Accepts GPC Biotech's Satraplatin NDA for Filing and Grants Priority Review Status
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Mar 2007
Satraplatin Phase 3 SPARC Trial - Additional Data Presented at European Association of Urology Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Mar 2007
Additional Data from Satraplatin SPARC Phase 3 Trial Presented at European Association of Urology Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Feb 2007
Satraplatin Shown to Significantly Reduce Risk of Disease Progression in Advanced Hormone-Refractory Prostate Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Feb 2007
Spectrum Pharmaceuticals Announces Satraplatin Data Presentation at the American Society of Clinical Oncology Prostate Cancer Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Feb 2007
GPC Biotech Launches Expanded Access Program for Oncology Drug Candidate Satraplatin in the U.S.
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Feb 2007
GPC Biotech Submits NDA for Lead Oncology Drug Candidate Satraplatin
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Feb 2007
Spectrum Pharmaceuticals Announces Completion of NDA Filing for Satraplatin for Hormone Refractory Prostate Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Jan 2007
YM BioSciences announces termination of the tesmilifene Phase III pivotal trial in advanced breast cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Jan 2007
European Association of Nuclear Medicine Journal Article Reports New Data Regarding Administration of QUADRAMET(R) with Chemotherapy in Hormone Refractory Prostate Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Sep 2006
Spectrum Pharmaceuticals Announces Positive Results of Satraplatin Pivotal Phase 3 Trial in Patients with Hormone-Refractory Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Sep 2006
Pharmion Corporation and GPC Biotech Announce Positive Results from the Satraplatin Pivotal Phase 3 Trial and Achievement of the Progression-Free Survival Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Sep 2006
EntreMed Commences Panzem(R) NCD Phase 2 Study in Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 May 2006
Independent Data Monitoring Board Recommends Expedited Interim Analysis of Overall Survival Data for Satraplatin Phase 3 Trial
Biopharmaceuticals
 HSMN NewsFeed - 16 May 2006
Pharmion Announces Start of Phase 1 Trial Evaluating Satraplatin Plus Xeloda(R) in Patients With Advanced Solid Tumors
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 43

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 43 additional stories matching:
HRPC
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.